Better Late Than Never, J&J’s Innovation Centers Start Opening For Business
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.
You may also be interested in...
Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace
J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.
J&J Starts The Year With A Bang With 22 Early-Stage Deals
The new collaborations cross the company’s diversified business, with an emphasis in pharma on drug discovery and early-stage research in collaboration with biotech and academia.
Merck’s Iain Dukes On New BD Culture: Regional Hubs And Sourcing Innovation
Since Dukes arrived six months ago as head of Merck Research Labs’ licensing and external affairs, Merck has consolidated and restructured its scattered business development functions, rolled out its regional BD hubs, and rationalized the distinction between equity investments and venture fund investments